Brief: Acorda Therapeutics And Chance Pharmaceuticals Announce Agreement To Commercialize Inbrija In China
08/05/2023 15:37
May 8 (Reuters) - Acorda Therapeutics Inc ACOR.O :
* ACORDA THERAPEUTICS AND CHANCE PHARMACEUTICALS ANNOUNCE
AGREEMENT TO COMMERCIALIZE INBRIJA® IN CHINA
* ACORDA THERAPEUTICS INC- UNDER TERMS OF AGREEMENTS, ACORDA
WILL
RECEIVE AN UP-FRONT PAYMENT OF $2.5 MILLION, A NEAR TERM
MILESTONE PAYMENT OF UP TO $6 MILLION
* ACORDA THERAPEUTICS INC- UNDER DEAL, CO TO GET $3 MILLION
UPON
REGULATORY APPROVAL, UP TO $132.5 MILLION IN SALES MILESTONES
* ACORDA THERAPEUTICS INC- UNDER DEAL CO TO ALSO GET A FIXED
FEE
FOR EACH CARTON OF INBRIJA SUPPLIED TO CHANCE
Source text for Eikon: ID:nBw4G2PD9a
Further company coverage: ACOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease